Evorpacept
- Generic Name
- Evorpacept
- Drug Type
- Biotech
- CAS Number
- 2484949-51-9
- Unique Ingredient Identifier
- X7K762X1IJ
- Background
evorpacept is under investigation in clinical trial NCT04755244 (A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)).
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- Conditions
- Plasma Cell Myeloma Refractory
- Interventions
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 197
- Registration Number
- NCT04643002
- Locations
- 🇬🇷
Investigational Site Number : 3000001, Athens, Greece
🇺🇸University of Michigan Health System - Ann Arbor- Site Number : 8400004, Ann Arbor, Michigan, United States
🇺🇸Roswell Park Cancer Institute- Site Number : 8400008, Buffalo, New York, United States
A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)
- Conditions
- Higher Risk Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- ALX Oncology Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT04417517
- Locations
- 🇺🇸
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸IU Simon Cancer Center, Indianapolis, Indiana, United States
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
- Conditions
- Metastatic CancerNonHodgkin LymphomaAdvanced CancerSolid Tumor
- Interventions
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- ALX Oncology Inc.
- Target Recruit Count
- 174
- Registration Number
- NCT03013218
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.